Matinas BioPharma Holdings, Inc. (MTNB)
| Market Cap | 30.59M |
| Revenue (ttm) | 4.28M |
| Net Income (ttm) | -20.67M |
| Shares Out | 228.30M |
| EPS (ttm) | -0.11 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 138,997 |
| Open | 0.132 |
| Previous Close | 0.130 |
| Day's Range | 0.130 - 0.140 |
| 52-Week Range | 0.110 - 0.890 |
| Beta | 2.02 |
| Analysts | Strong Buy |
| Price Target | 3.00 (+2,138.81%) |
| Earnings Date | Nov 1, 2023 |
About MTNB
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is LYPDISO, a prescription-only omega-3 fatty acid-based composition intended for the treatment of cardiovascular and m... [Read more]
Financial Performance
In 2022, MTNB's revenue was $3.19 million, an increase of 9560.61% compared to the previous year's $33,000. Losses were -$21.00 million, -11.33% less than in 2021.
Financial StatementsAnalyst Forecast
According to one analyst, the rating for MTNB stock is "Strong Buy" and the 12-month stock price forecast is $3.0.
News
Matinas BioPharma Announces Notification of NYSE American Continued Listing Deficiency
BEDMINSTER, N.J., Sept. 22, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of small molec...
Matinas BioPharma to Participate in the H.C. Wainwright Global Investment Conference
BEDMINSTER, N.J., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery...
Matinas BioPharma Announces Publication of Results from the Phase 2 EnACT Clinical Trial of MAT2203 in the IDSA Journal Clinical Infectious Diseases
BEDMINSTER, N.J., Aug. 22, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid n...
Matinas BioPharma to Participate in the BTIG Virtual Biotechnology Conference 2023
BEDMINSTER, N.J., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery ...
Matinas BioPharma to Webcast Conference Call to Discuss Second Quarter 2023 Financial Results and Provide a Business Update on August 9, 2023
BEDMINSTER, N.J., July 26, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracel...
Matinas BioPharma to Present at the JMP Securities Life Sciences Conference on May 15, 2023
BEDMINSTER, N.J., May 11, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid na...
Matinas BioPharma Reports First Quarter 2023 Financial Results and Provides a Business Update
FDA feedback from Type B meeting reiterated the Agency's intent to work collaboratively in advancing development of MAT2203 for the treatment of invasive fungal infections (IFIs)
Matinas BioPharma to Webcast Conference Call to Discuss First Quarter 2023 Financial Results and Provide a Business Update on May 10, 2023
BEDMINSTER, N.J., May 03, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery o...
Matinas BioPharma Reports 2022 Financial Results and Provides a Business Update
Near-term data readouts from internal and collaborative programs expected to support advancement of the LNC platform for delivery of nucleic acids
Matinas BioPharma to Webcast Conference Call to Discuss 2022 Financial Results and Provide a Business Update on March 15, 2023
BEDMINSTER, N.J., March 08, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular deliver...
Matinas BioPharma Announces that MAT2203 Will Be Featured in Two Oral Presentations at ECCMID
BEDMINSTER, N.J., March 02, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid ...
Matinas BioPharma Provides Business Update and 2023 Strategic Outlook
2022 Success Has Increased Confidence to Focus LNC Delivery Platform on the Future of Medicine - Delivering Genes
Matinas BioPharma to Provide Corporate Update and 2023 Business Outlook on January 30, 2023
Conference call and live audio webcast scheduled for Monday, January 30th at 4:30 p.m. ET Conference call and live audio webcast scheduled for Monday, January 30th at 4:30 p.m. ET
Adolore Biotherapeutics Strengthens Management Team and Board of Directors with the Appointments of Roelof Rongen, MSE, MBA and Mark C. Rogers, MD, MBA
Mr. Rongen appointed as CEO and member of the Board bringing 30 years of executive leadership experience and expertise across a number of therapeutic areas Bolstered expertise on Board of Directors wi...
Matinas BioPharma Announces Collaboration with National Resilience to Explore and Evaluate Novel LNC Platform Delivery Technology for Certain Nucleic Acids
BEDMINSTER, N.J., Jan. 12, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of nucleic acids an...
Matinas BioPharma Reports Third Quarter 2022 Financial Results and Highlights Recent Progress
EnACT Phase 2 study of MAT2203 in cryptococcal meningitis met its primary endpoint with 95% two-week patient survival in the Cohort 4 all-oral regimen
Matinas BioPharma Announces Positive Interim Data from the Phase 2 EnACT Trial of MAT2203 for the Treatment of Cryptococcal Meningitis, Exceeding Primary Endpoint Threshold; Patient Survival in All-Oral Cohort 4 Regimen Currently 90%
Two-week survival in Cohort 4 (all-oral regimen) was 95% in 40 patients receiving MAT2203
Matinas BioPharma to Present at the ThinkEquity Annual Global Investment Conference
BEDMINSTER, N.J., Oct. 21, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of nucleic acids and...
Matinas BioPharma Announces Infectious Diseases Society of America (IDSA) has Selected the EnACT Phase 2 Trial Abstract of MAT2203 as its Outstanding Abstract and IDSA Awardee For IDWeek 2022
BEDMINSTER, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of nu...
Matinas BioPharma to Present New MAT2203 (Oral Amphotericin B) Data During IDWeek 2022
Interim data from all-oral Cohort 4 of the EnACT Trial of MAT2203 in Cryptococcal Meningitis to be revealed along with an overview of the entire Phase 2 trial
Matinas BioPharma Announces Chairman Succession Plan
Eric J. Ende, MD, MBA Appointed as Chairman, Effective October 1, 2022; Founding Chairman Herbert J. Conrad to Remain an Independent Director of the Company Eric J. Ende, MD, MBA Appointed as Chairman...
Matinas BioPharma Reports Second Quarter 2022 Financial Results and Highlights Recent Progress
75% of Patients Enrolled to Date in Cohort 4 of EnACT (MAT2203 in Cryptococcal Meningitis); Topline Data in Late Q3/Early Q4 2022
Matinas BioPharma to Participate in the BTIG Biotechnology Conference
BEDMINSTER, N.J., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of nucleic acids and...
Matinas BioPharma to Webcast Conference Call Discussing Second Quarter 2022 Financial and Operational Results on August 11, 2022
BEDMINSTER, N.J., July 28, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of nu...
Matinas BioPharma Announces Positive Opinion by the European Medicines Agency on Orphan Drug Designation for MAT2203 for the Treatment of Cryptococcosis
BEDMINSTER, N.J., July 25, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of nucleic acids and...